Efficacy and safety of nivolumab plus ipilimumab in gastrointestinal cancers: a systematic review and meta-analysis
IntroductionGastrointestinal (GI) cancers represent a significant global health burden, and the need for more effective treatment options is exceptionally pressing. The present meta-analysis aimed to explore the efficacy and safety of the combination of nivolumab and ipilimumab in treating GI cancer...
Saved in:
| Main Authors: | Bowen Dai, Jiaping Jiang, Xiaoyu Yu, Haihua Zhan, Zhengchuan Hu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1515992/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Colitis grave inmunomediada por Nivolumab-Ipilimumab: a propósito de un caso
by: Maria Victoria Foglino, et al.
Published: (2025-07-01) -
Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
by: Valerie Glutsch, et al.
Published: (2024-12-01) -
Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database
by: Xianyu Dai, et al.
Published: (2025-07-01) -
Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study
by: Jung Sun Kim, et al.
Published: (2025-06-01) -
Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan
by: Tomoki Taniguchi, et al.
Published: (2024-12-01)